Type III hyperlipoproteinemia (HLP III) is characterized by the reduce
d catabolism and accumulation of chylomicron and very low density lipo
protein (VLDL) remnants. Most HLP III patients are homozygous for the
apolipoprotein E2 (Cys(112), Cys(158)) allele; however, several other
mutations at this gene locus have been associated with this HLP. In or
der to assess the presence of rare apo E variants in our population, w
e have examined apo E phenotypes by isoelectric focusing (IEF) and gen
otypes by restriction enzyme analysis of polymerase chain reaction (PC
R) amplified DNA in 15 patients with HLP III. Lack of concordance betw
een these two methods was observed in 11 subjects (73.3%). DNA sequenc
ing analysis of the receptor binding domain of the apo E gene in the 1
1 HLP III patients with discrepancies demonstrated the presence of six
carriers of the epsilon 3 (Arg(136) --> Ser) allele and three carrier
s of the epsilon 2 (Gly(127) --> Asp) allele. Five HLP III patients we
re apo E2/E2 using IEF, but only 2 of them were epsilon 2 homozygous u
sing PCR. Two patients were E3/E3 homozygous with normal DNA sequence
in the low density lipoprotein receptor binding domain of apo E. In co
nclusion, our results show that a number of different apo E genotypes
are associated with HLP III in this population. More specifically, mut
ations at positions 127 and 136 might be frequent in Spain and occur i
n patients with HLP III.